ADAR1 Capital Management
ADAR1 Capital Management reported 262 stocks worth $2.1B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are ABVX (11.4%), PTGX (5.6%) and ROIV (5.3%). Compared with Q1 2026, the fund opened new positions in EDIT, VOR and FTH, added to ABVX, SPY and ZLAB, trimmed PTGX, ROIV and IMVT and sold out of BEAM, SRRK and VRTX.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  ABVX Abivax SA | $240M | 11.4% | 1.8M | +411K (+29%) | 8 of 8 | |
| 2 |  PTGX Protagonist Therapeutics Inc | $118M | 5.6% | 961K | −33K (−3%) | 8 of 8 | |
| 3 |  ROIV Roivant Sciences Ltd | $112M | 5.3% | 3.2M | −129K (−4%) | 8 of 8 | |
| 4 |  SPY Spdr S&P 500 ETF TR | $96.4M | 4.6% | 129K | +53K (+70%) | 5 of 8 | |
| 5 |  IMVT Immunovant Inc | $89.8M | 4.3% | 2.3M | −348K (−13%) | 8 of 8 | |
| 6 |  ZLAB Zai Lab Ltd | $64M | 3.0% | 3.4M | +1.9M (+136%) | 8 of 8 | |
| 7 |  AGIO Agios Pharmaceuticals Inc | $47.8M | 2.3% | 1.3M | +1.1M (+816%) | 7 of 8 | |
| 8 | CRINETICS PHARMACEUTICALS IN | $45.7M | 2.2% | 1.2M | +83K (+7%) | 8 of 8 | |
| 9 |  BOXX EA Series Trust | $39.5M | 1.9% | 337K | No change | 8 of 8 | |
| 10 |  CYTK Cytokinetics Inc | $39M | 1.9% | 458K | −175K (−28%) | 8 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
TERNS PHARMACEUTICALS INC | $48.2M | 915K |
 BEAM Beam Therapeutics Inc | $34.5M | 1.4M |
 SRRK Scholar Rock Hldg Corp | $20M | 407K |
 VRTX Vertex Pharmaceuticals I | $6.7M | 15K |
 VRDN Viridian Therapeutics Inc | $6M | 304K |
🔒 Free account: see all 30.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
 IWM Ishares TR | Put | $18.8M | 63K | +35,000 |
SPY Spdr S&P 500 ETF TR | Put | $18.7M | 25K | +25,000 |
 XBI Spdr Series Trust | Put | $10.7M | 67K | +52,400 |
ABVX Abivax SA | Call | $5.9M | 44K | +400 |
 KVACF Keen Vision Acquisition Corp | Call | $930K | 75K | 0 |
🔒 Free account: see all 10.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →ADAR1 Capital Management 13F FAQ
What does ADAR1 Capital Management own?
ADAR1 Capital Management reported 262 stocks worth $2.1B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are ABVX (11.4%), PTGX (5.6%) and ROIV (5.3%). The table above lists every position in the filing (the top 10 without an account).
What did ADAR1 Capital Management buy and sell in Q2 2026?
Compared with Q1 2026: 43 new positions, 96 added to, 64 trimmed and 72 sold out. New positions include EDIT, VOR and FTH. It sold all of BEAM, SRRK and VRTX.
When will ADAR1 Capital Management file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is ADAR1 Capital Management's portfolio worth?
The Q2 2026 filing reports $2.1B in US stocks ($2.2B including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.